Epilepsy, a neurological condition marked by repeated seizures, impacts millions globally. Though pharmaceuticals have traditionally been the mainstay of treatment, the realm of epilepsy care is evolving, with neuromodulation devices introducing promising innovations. As a result, the neuromodulation devices market is forecast to see a steady expansion in the coming years, according to GlobalData, a leading data and analytics company.

Epilepsy is a seizure disorder that stems from abnormal electrical discharges in the brain and manifests in various forms, from loss of awareness to full-body seizures. This disorder, with its diverse causes and severities, presents a formidable challenge to healthcare professionals and patients alike. While some epilepsies have known genetic factors, others remain enigmatic in origin.

Thomas Fleming, Medical Analyst at GlobalData, comments: “Neuromodulation devices are often used to treat severe, but not life-threatening conditions. The neuromodulation device market was negatively impacted by the COVID-19 pandemic, as procedures that were deemed not to be life-threatening were pushed to the side. However, GlobalData predicts consistent growth for the neuromodulation market in the near future.”

Despite its prevalence, epilepsy treatment options have historically been limited. However, neuromodulation devices, such as Deep Brain Stimulators (DBS) and Vagus Nerve Stimulators (VNS), offer innovative approaches to seizure management.

A DBS is a device that is comprised of a brain-oriented pacemaker (an implantable pulse generator) that sends electrical stimulation through surgically implanted electrodes to specific targets in the brain. A VNS is a device comprised of an electrical pacemaker that sends electrical stimulation through surgically implanted electrodes to target the vagus nerve. Both technologies modulate neural activity to potentially reduce seizure frequency and severity.

Fleming concludes: “GlobalData’s latest models predict positive mid-single digit growth for the neuromodulation devices market in terms of market share, with segments such as DBS and VNS seeing compound annual growth rate (CAGR) of 6.53% and 5.92% between 2023 and 2033, respectively.”